<DOC>
	<DOCNO>NCT02047513</DOCNO>
	<brief_summary>NEONAX interventional , prospective , randomize , control , open label , two side survival phase II study fix survival probability , unconnected analysis result experimental arm . Determining impact 2 cycle Perioperative nab-paclitaxel/gemcitabine follow surgery 4 cycle adjuvant nab-paclitaxel/gemcitabine 6 cycle adjuvant nab-paclitaxel/gemcitabine Disease free survival ( DFS ) rate 18 month post randomization</brief_summary>
	<brief_title>Neoadjuvant Plus Adjuvant Only Adjuvant Nab- Paclitaxel Plus Gemcitabine Resectable Pancreatic Cancer</brief_title>
	<detailed_description>The plan trial enable u address follow issue : - Identification patient benefit surgery . Tumor progress intensify Perioperative chemotherapy likely indicate particularly poor prognosis suggest patient would benefit immediate surgery . - Assess tumor response/downsizing use nab-paclitaxel/gemcitabine also molecular level - Can achieve good systemic tumor control reduce metastatic spread use nab-paclitaxel/gemcitabine compare adjuvant gemcitabine - Examining effect efficacious chemotherapy regimen ( nab-paclitaxel/gemcitabine ) adjuvant set - Defining impact perioperative adjuvant chemotherapy gemcitabine/nab-paclitaxel DFS 3-year Overall survival ( OS ) Histopathological tumor regression evaluate addition tumor size measurement accord Response Evaluation Criteria In Solid Tumors ( RECIST ) . We establish histopathological tumor regression score evaluate efficacy neoadjuvant treatment . For score examine tumor core biopsy obtain prior neoadjuvant treatment histological tumor specimen surgery arm . To reliably determine R0 resection , resect specimen prepared pathology define manner accord procedure set German S3 guideline pancreatic cancer . This trial provide unique opportunity pancreatic cancer obtain material prior surgery biomarker analysis correlation outcome . We perform pharmacogenomic candidate gene analysis hENT1 ( human equilibrative nucleoside transporter-1 ) , CDA ( cell differentiation agent ) , DCK ( Desoxycytidin-Kinase ) 5´nucleotidase arm .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Inclusion criterion : Histologically cytological confirmed , clearly resectable ductal adenocarcinoma pancreas ( PDAC ) ≤ cT3 prior tumor specific treatment . No evidence metastases distant organ ( e.g . liver , peritoneum , lung ) . Resectable tumor . Determination resectability base spiral CT scan oral i.v . contrast enhancement MRI use recent consensus definition ( Resectability : Clear fat plane around celiac artery , hepatic artery superior mesenteric artery . ) ECOG performance status 0 1 Creatinine clearance ≤ 30 ml/min Serum total bilirubin level ≤ 2.5 x ULN ( necessary enrollment randomization , start neoadjuvant chemotherapy arm A ) ALT AST ≤ 2.5 x ULN ( necessary enrollment randomization , start neoadjuvant chemotherapy arm A ) In case biliary obstruction , biliary decompression require patient randomize receive neoadjuvant chemotherapy ( arm A ) White blood cell count ≥ 3.5 x 106/ml , neutrophil granulocytes count ≥ 1,5 x 106/ml , platelet count ≥ 100 x 106/ml Signed inform consent incl . participation translational research Age ≥ 18 year Exclusion criterion : Borderline resectable PDAC radiologic criterion Papillary cancer Neuroendocrine Cancer Tumor specific pretreatment Local recurrence Peritoneal distant metastasis Radiographic evidence severe portal hypertension/cavernous transformation Infiltration extrapancreatic organ ( except duodenum ) Ascites Gastric outlet obstruction Global respiratory insufficiency require oxygen supplementation Chronic infectious disease , immune deficiency syndrome Premalignant hematologic disorder , e.g . myelodysplastic syndrome Disability understand sign write informed consent document Past current history malignancy except indication study curatively treat : Basal squamous cell carcinoma skin Insitu carcinoma cervix Other malignant disease without recurrence least 2 year followup Clinically significant cardiovascular disease ( incl . myocardial infarction , unstable angina , symptomatic congestive heart failure , serious uncontrolled cardiac arrhythmia ) 6 month enrollment Clinically relevant history interstitial lung disease , e.g . noninfectious pneumonitis pulmonary fibrosis evidence interstitial lung disease baseline chest CT scan chest xray . History evidence upon physical examination CNS disease unless adequately treat ( e.g . primary brain tumor , seizure control standard medical therapy history stroke ) . Preexisting neuropathy &gt; grade 1 ( NCI CTCAE ) Allogeneic transplantation require immunosuppressive therapy major immunosuppressive therapy Severe nonhealing wound , ulcer bone fraction Evidence bleed diathesis coagulopathy Patients receive therapeutic anticoagulation must INR &lt; 1.5 ULN PTT &lt; 1.5 ULN within 28 day prior randomization . The use full dose anticoagulant allow long INR PTT within therapeutic limit ( accord medical standard institution ) Major surgical procedure , except open biopsy , significant traumatic injury within 28 day prior randomization , anticipation need major surgical procedure course study except surgery pancreatic cancer curative intent central intravenous line placement chemotherapy administration . Pregnancy breastfeed woman . Subjects know allergy study drug excipients . Current recent ( within 28 day prior randomization ) treatment another investigational drug participation another investigational study . Any psychological , familial , sociological geographical condition potentially compromise compliance study protocol followup schedule ; condition discuss patient prior registration trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>